CompletedPhase 3

A Comparison of Valganciclovir and Ganciclovir in the Treatment of Cytomegalovirus (CMV) of the Eyes

United StatesStarted 1997-01

Plain-language summary

To investigate the efficacy and safety of RS-79070 when used as induction therapy in patients with newly diagnosed peripheral retinitis. To assess the effects of induction and maintenance level dosing of RS-79070 on CMV viral load, estimated by plasma CMV PCR. To assess the pharmacokinetics of ganciclovir following administration of RS-79070 in the target population.

Who can participate

Age range14 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Documented AIDS diagnosis * Newly diagnosed peripheral CMV retinitis * More than 3 weeks of previous therapy for CMV retinitis

Trial details

NCT IDNCT00002377

SponsorHoffmann-La Roche

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2002-12

View on ClinicalTrials.gov More Cytomegalovirus Retinitis trials